JP2021525725A5 - - Google Patents

Info

Publication number
JP2021525725A5
JP2021525725A5 JP2020566618A JP2020566618A JP2021525725A5 JP 2021525725 A5 JP2021525725 A5 JP 2021525725A5 JP 2020566618 A JP2020566618 A JP 2020566618A JP 2020566618 A JP2020566618 A JP 2020566618A JP 2021525725 A5 JP2021525725 A5 JP 2021525725A5
Authority
JP
Japan
Prior art keywords
composition according
composition
antigen
multiple doses
mrna
Prior art date
Application number
JP2020566618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525725A (ja
JPWO2019232103A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034474 external-priority patent/WO2019232103A1/en
Publication of JP2021525725A publication Critical patent/JP2021525725A/ja
Publication of JP2021525725A5 publication Critical patent/JP2021525725A5/ja
Publication of JPWO2019232103A5 publication Critical patent/JPWO2019232103A5/ja
Priority to JP2024187919A priority Critical patent/JP2025020205A/ja
Pending legal-status Critical Current

Links

JP2020566618A 2018-05-30 2019-05-29 メッセンジャーrnaワクチンおよびその使用 Pending JP2021525725A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024187919A JP2025020205A (ja) 2018-05-30 2024-10-25 メッセンジャーrnaワクチンおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678225P 2018-05-30 2018-05-30
US62/678,225 2018-05-30
PCT/US2019/034474 WO2019232103A1 (en) 2018-05-30 2019-05-29 Messenger rna vaccines and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024187919A Division JP2025020205A (ja) 2018-05-30 2024-10-25 メッセンジャーrnaワクチンおよびその使用

Publications (3)

Publication Number Publication Date
JP2021525725A JP2021525725A (ja) 2021-09-27
JP2021525725A5 true JP2021525725A5 (https=) 2022-06-06
JPWO2019232103A5 JPWO2019232103A5 (https=) 2022-06-06

Family

ID=66952034

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566618A Pending JP2021525725A (ja) 2018-05-30 2019-05-29 メッセンジャーrnaワクチンおよびその使用
JP2024187919A Pending JP2025020205A (ja) 2018-05-30 2024-10-25 メッセンジャーrnaワクチンおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024187919A Pending JP2025020205A (ja) 2018-05-30 2024-10-25 メッセンジャーrnaワクチンおよびその使用

Country Status (9)

Country Link
US (2) US20200016274A1 (https=)
EP (1) EP3801467A1 (https=)
JP (2) JP2021525725A (https=)
KR (1) KR20210056953A (https=)
CN (2) CN118436618A (https=)
AU (2) AU2019277361B2 (https=)
CA (1) CA3101454A1 (https=)
SG (1) SG11202011587PA (https=)
WO (1) WO2019232103A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
MX2016005238A (es) * 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
BR112021022909A2 (pt) * 2019-05-14 2022-01-25 Translate Bio Inc Processo aprimorado de preparação de nanopartículas lipídicas carregadas com mrna
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
JP7744354B2 (ja) * 2020-02-25 2025-09-25 トランスレイト バイオ, インコーポレイテッド Mrna担持脂質ナノ粒子を調製する改善された方法
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2023546175A (ja) 2020-10-14 2023-11-01 ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド 脂質ナノ粒子製造の方法及びそれに由来する組成物
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
US20240148897A1 (en) 2021-03-08 2024-05-09 Eyegene Inc. Composition for in vivo delivery of rna and preperation method therefor
NL2028681B1 (en) * 2021-04-02 2022-10-17 Nutcracker Therapeutics Inc Materials and methods for generating antigen-specific t cells and treating diseases
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
US12570977B2 (en) * 2021-06-12 2026-03-10 Mello Biotech Taiwan Co., Ltd. mRNA composition and production method for use in anti-viral and anti-cancer vaccines
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
CN114344278B (zh) * 2022-01-19 2023-06-06 南京吉迈生物技术有限公司 核酸递送载体及其应用
JPWO2023145755A1 (https=) * 2022-01-25 2023-08-03
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6645495B1 (en) 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
MX342785B (es) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
US9555089B2 (en) 2009-08-18 2017-01-31 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
HUE042177T2 (hu) 2009-12-01 2019-06-28 Translate Bio Inc Szteroidszármazék mRNS szállítására humán genetikai betegségekben
EP3354644A1 (en) 2011-06-08 2018-08-01 Translate Bio, Inc. Cleavable lipids
PL3586861T3 (pl) * 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체
ES2762873T3 (es) 2012-03-29 2020-05-26 Translate Bio Inc Lípidos catiónicos ionizables
SG11201507474QA (en) * 2013-03-14 2015-10-29 Shire Human Genetic Therapies RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
ES2707966T3 (es) * 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
AU2014340149B2 (en) * 2013-10-22 2020-12-24 Shire Human Genetic Therapies, Inc. CNS delivery of mRNA and uses thereof
MX2016005238A (es) * 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
EA034103B1 (ru) * 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
SMT202200502T1 (it) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
BR112016030852A2 (pt) 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016090262A1 (en) * 2014-12-05 2016-06-09 Shire Human Genetic Therapies, Inc. Messenger rna therapy for treatment of articular disease
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016118725A1 (en) 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
LT3313829T (lt) 2015-06-29 2024-08-12 Acuitas Therapeutics Inc. Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3397613A1 (en) 2015-12-30 2018-11-07 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
TWI773666B (zh) 2016-03-30 2022-08-11 美商英特利亞醫療公司 Crispr/cas 組分之脂質奈米粒子調配物
CA3027312A1 (en) * 2016-06-13 2017-12-21 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
SG11201903674YA (en) * 2016-10-26 2019-05-30 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
BR112019008481A2 (pt) * 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
WO2018089801A1 (en) * 2016-11-10 2018-05-17 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
EP3641834B1 (en) * 2017-06-19 2023-10-04 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
MX2020011166A (es) 2018-04-25 2022-10-19 Ethris Gmbh Agentes crioprotectores para formulaciones en forma de particulas.
CA3101484A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Phosphoester cationic lipids
JP7463006B2 (ja) 2018-05-30 2024-04-08 トランスレイト バイオ, インコーポレイテッド ステロイド性部分を含むカチオン性脂質
WO2019232095A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Vitamin cationic lipids
US20220226244A1 (en) 2019-05-31 2022-07-21 Translate Bio, Inc. Macrocyclic lipids
US12053551B2 (en) 2019-12-20 2024-08-06 Translate Bio, Inc. Process of preparing mRNA-loaded lipid nanoparticles

Similar Documents

Publication Publication Date Title
JP2021525725A5 (https=)
JPWO2019232103A5 (https=)
US20250145577A1 (en) Stereochemically enriched compositions for delivery of nucleic acids
US10899830B2 (en) Methods and compositions for delivering MRNA coded antibodies
US20250152739A1 (en) Composition and methods for treatment of ornithine transcarbamylase deficiency
ES2740248T3 (es) Composiciones de nanopartículas lipídicas y métodos para la administración ARNm
JP2026001042A (ja) ポリサルコシンを含むrna粒子
US20200016274A1 (en) Messenger rna vaccines and uses thereof
ES2968649T3 (es) Nanopartículas lipídicas para la administración de ARNm en los pulmones
JP2023549265A (ja) 脂質ナノ粒子mRNAワクチンの安定化のための組成物および方法
AU2019378763A1 (en) Methods for inducing immune tolerance
US20230226147A1 (en) Composition and methods for treatment of primary ciliary dyskinesia
US20250009863A1 (en) Lyme disease rna vaccine
US20240335511A1 (en) Therapeutic rna for treating cancer
US20250161425A1 (en) Signal sequences for nucleic acid vaccines
US20230145774A1 (en) Treatment involving non-immunogenic rna for antigen vaccination
US20240307556A1 (en) Compositions and methods for reverse gene therapy
JP2024540948A (ja) 異なる投与のrnaを投与するための組成物
RU2792644C2 (ru) Рнк-частицы, включающие полисаркозин
US20240390462A1 (en) Treatment Schedule for Cytokine Proteins
TW202402305A (zh) 癌症治療之免疫增強
NZ618275B2 (en) Lipid nanoparticle compositions and methods for mrna delivery